{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:54:53Z","timestamp":1793328893987,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shaanxi Province Key Industry Innovation Chain","award":["2024SF-ZDCYL-02-06"],"award-info":[{"award-number":["2024SF-ZDCYL-02-06"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82122033"],"award-info":[{"award-number":["82122033"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92259304"],"award-info":[{"award-number":["92259304"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402323"],"award-info":[{"award-number":["82402323"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00259-025-07362-4","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:37:20Z","timestamp":1748302640000},"page":"4939-4951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers"],"prefix":"10.1007","volume":"52","author":[{"given":"Jiajun","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoqi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"8015","key":"7362_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","volume":"630","author":"X Cui","year":"2024","unstructured":"Cui X, Li Z, Kong Z, Liu Y, Meng H, Wen Z, et al. Covalent targeted radioligands potentiate radionuclide therapy. Nature. 2024;630(8015):206\u201313.","journal-title":"Nature"},{"issue":"9","key":"7362_CR2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-Based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322.","journal-title":"J Nucl Med"},{"issue":"5\u20136","key":"7362_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/prca.201300095","volume":"8","author":"EJ Hamson","year":"2014","unstructured":"Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteom \u2013 Clin Appl. 2014;8(5\u20136):454\u201363.","journal-title":"Proteom\u2013 Clin Appl"},{"issue":"6","key":"7362_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of Cancer. J Nucl Med. 2019;60(6):801\u20135.","journal-title":"J Nucl Med"},{"issue":"8","key":"7362_CR5","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2967\/jnumed.123.265486","volume":"64","author":"T Watabe","year":"2023","unstructured":"Watabe T, Naka S, Tatsumi M, Kamiya T, Kimura T, Shintani Y, et al. Initial evaluation of (18F)FAPI-74 PET for various histopathologically confirmed cancers and benign lesions. J Nucl Med. 2023;64(8):1225.","journal-title":"J Nucl Med"},{"issue":"3","key":"7362_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-021-05554-2","volume":"49","author":"Y Liu","year":"2022","unstructured":"Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, et al. Fibroblast activation protein targeted therapy using (177Lu)FAPI-46 compared with (225Ac)FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2022;49(3):871\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7362_CR7","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1007\/s00259-023-06230-3","volume":"50","author":"Y Liu","year":"2023","unstructured":"Liu Y, Tang H, Song T, Xu M, Chen J, Cui X, et al. Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2023;50(9):2636\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7362_CR8","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1111\/cas.16285","volume":"115","author":"S Meng","year":"2024","unstructured":"Meng S, Hara T, Miura Y, Ishii H. Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T-cell therapy in solid tumors. Cancer Sci. 2024;115(11):3532\u201342.","journal-title":"Cancer Sci"},{"issue":"7","key":"7362_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1021\/acs.bioconjchem.3c00244","volume":"34","author":"A Zana","year":"2023","unstructured":"Zana A, Puig-Moreno C, Bocci M, Gilardoni E, Di Nitto C, Principi L, et al. A comparative analysis of fibroblast activation Protein-Targeted small Molecule\u2013Drug, Antibody\u2013Drug, and Peptide\u2013Drug conjugates. Bioconjug Chem. 2023;34(7):1205\u201311.","journal-title":"Bioconjug Chem"},{"key":"7362_CR10","doi-asserted-by":"publisher","first-page":"111330","DOI":"10.1016\/j.apradiso.2024.111330","volume":"209","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wu Y, Lu W, Xiao Y, Liu S, Yu J. Carborane-FAPI conjugate: A potential FAP-targeted Boron agent with improved Boron content. Appl Radiat Isot. 2024;209:111330.","journal-title":"Appl Radiat Isot"},{"issue":"8","key":"7362_CR11","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","volume":"49","author":"M Li","year":"2022","unstructured":"Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022;49(8):2844\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Supplement 1","key":"7362_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2967\/jnumed.123.266983","volume":"65","author":"L Zhao","year":"2024","unstructured":"Zhao L, Kang F, Pang Y, Fang J, Sun L, Wu H, et al. Fibroblast activation protein inhibitor tracers and their preclinical, translational, and clinical status in China. J Nucl Med. 2024;65(Supplement 1):4.","journal-title":"J Nucl Med"},{"issue":"9","key":"7362_CR13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nprot.2015.090","volume":"10","author":"Z Liu","year":"2015","unstructured":"Liu Z, Lin K, B\u00e9nard F, Pourghiasian M, Kiesewetter DO, Perrin DM, et al. One-step (18F) labeling of biomolecules using organotrifluoroborates. Nat Protoc. 2015;10(9):1423\u201332.","journal-title":"Nat Protoc"},{"issue":"12","key":"7362_CR14","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.2967\/jnumed.123.265715","volume":"64","author":"X Li","year":"2023","unstructured":"Li X, Ye J, Wang J, Quan Z, Li G, Ma W, et al. First-in-Humans PET imaging of KRASG12C mutation status in Non\u2013Small cell lung and colorectal Cancer patients using (18F)PFPMD. J Nucl Med. 2023;64(12):1880\u20138.","journal-title":"J Nucl Med"},{"issue":"4","key":"7362_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.2967\/jnumed.123.265929","volume":"65","author":"G Li","year":"2024","unstructured":"Li G, Ma W, Li X, Yang W, Quan Z, Ma T, et al. Performance evaluation of the uMI panorama PET\/CT system in accordance with the National electrical manufacturers association NU 2-2018 standard. J Nucl Med. 2024;65(4):652\u20138.","journal-title":"J Nucl Med"},{"issue":"3","key":"7362_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S, PKSolver. An add-in program for Pharmacokinetic and pharmacodynamic data analysis in Microsoft excel. Comput Methods Programs Biomed. 2010;99(3):306\u201314.","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"7362_CR17","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/acs.molpharmaceut.2c00954","volume":"20","author":"J Ye","year":"2023","unstructured":"Ye J, Yang W, Xie Z, Yan Y, Li G, Li G, et al. Safety, biodistribution, and dosimetry study of meplazumab, a potential COVID-19 therapeutic drug, with (131I)-Labeling and SPECT imaging. Mol Pharm. 2023;20(3):1750\u20137.","journal-title":"Mol Pharm"},{"issue":"1","key":"7362_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00259-017-3817-y","volume":"45","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of (213Bismuth)-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45(1):31\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7362_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13550-017-0257-4","volume":"7","author":"CA Umbricht","year":"2017","unstructured":"Umbricht CA, Bene\u0161ov\u00e1 M, Schmid RM, T\u00fcrler A, Schibli R, van der Meulen NP, et al. (44Sc)-PSMA-617 for radiotheragnostics in tandem with (177Lu)-PSMA-617\u2014preclinical investigations in comparison with (68Ga)-PSMA-11 and (68Ga)-PSMA-617. EJNMMI Res. 2017;7(1):9.","journal-title":"EJNMMI Res"},{"key":"7362_CR20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0370","author":"JM Reyes-Gonz\u00e1lez","year":"2025","unstructured":"Reyes-Gonz\u00e1lez JM, Rajkumar H, Lee W, Baidoo KE, Edinger RS, Diehl G, et al. Evaluation of VLA-4 (integrin \u03b14\u03b21) as a shared target for radiopharmaceutical therapy across solid tumors. Mol Cancer Ther. 2025. https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0370.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"7362_CR21","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1021\/acs.molpharmaceut.0c00060","volume":"17","author":"JM Kelly","year":"2020","unstructured":"Kelly JM, Ponnala S, Amor-Coarasa A, Zia NA, Nikolopoulou A Jr, Williams C, et al. Preclinical evaluation of a High-Affinity Sarcophagine-Containing PSMA ligand for (64Cu)\/(67Cu)-Based theranostics in prostate Cancer. Mol Pharm. 2020;17(6):1954\u201362.","journal-title":"Mol Pharm"},{"issue":"24","key":"7362_CR22","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/cells13242065","volume":"13","author":"LD Punshon","year":"2024","unstructured":"Punshon LD, Fabbrizi MR, Phoenix B, Green S, Parsons JL. Current insights into the radiobiology of boron neutron capture therapy and the potential for further improving biological effectiveness. Cells. 2024;13(24):2065.","journal-title":"Cells."},{"issue":"4","key":"7362_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12149-019-01347-8","volume":"33","author":"K Ishiwata","year":"2019","unstructured":"Ishiwata K. 4-Borono-2-(18F)-fluoro-l-phenylalanine PET for Boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research. Ann Nucl Med. 2019;33(4):223\u201336.","journal-title":"Ann Nucl Med"},{"issue":"11","key":"7362_CR24","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1097\/RLU.0000000000005348","volume":"49","author":"M Kiani","year":"2024","unstructured":"Kiani M, Jokar S, Hassanzadeh L, Behnammanesh H, Bavi O, Beiki D, et al. Recent clinical implications of FAPI: imaging and therapy. Clin Nucl Med. 2024;49(11):e538\u201356.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"7362_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","volume":"46","author":"S Kuyumcu","year":"2021","unstructured":"Kuyumcu S, Kovan B, Sanli Y, Buyukkaya F, Has Simsek D, \u00f6zkan ZG, et al. Safety of fibroblast activation Protein\u2013Targeted radionuclide therapy by a Low-Dose dosimetric approach using (177Lu)-FAPI04. Clin Nucl Med. 2021;46(8):641\u20136.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"7362_CR26","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50(7):1906\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"23","key":"7362_CR27","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","volume":"29","author":"H Fu","year":"2023","unstructured":"Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W, et al. Fibroblast activation Protein-Targeted radioligand therapy with (177Lu)-EB-FAPI for metastatic Radioiodine-Refractory thyroid cancer: First-in-Human, Dose-Escalation study. Clin Cancer Res. 2023;29(23):4740\u201350.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"7362_CR28","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1007\/s00259-023-06282-5","volume":"50","author":"J Huang","year":"2023","unstructured":"Huang J, Fu L, Zhang X, Huang S, Dong Y, Hu K, et al. Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a (18F)-labeled glycopeptide-containing FAPI with (18F)FAPI-42. Eur J Nucl Med Mol Imaging. 2023;50(11):3363\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"7362_CR29","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.7150\/thno.87663","volume":"13","author":"HT Kuo","year":"2023","unstructured":"Kuo HT, Zhang Z, Zhang C, Merkens H, Tan R, Wong A, et al. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands. Theranostics. 2023;13(13):4559\u201373.","journal-title":"Theranostics"},{"key":"7362_CR30","doi-asserted-by":"publisher","first-page":"104275","DOI":"10.1016\/j.jinsphys.2021.104275","volume":"133","author":"CC Grula","year":"2021","unstructured":"Grula CC, Rinehart JP, Greenlee KJ, Bowsher JH. Body size allometry impacts flight-related morphology and metabolic rates in the solitary bee Megachile rotundata. J Insect Physiol. 2021;133:104275.","journal-title":"J Insect Physiol"},{"issue":"6","key":"7362_CR31","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"GK Sj\u00f6green","year":"2022","unstructured":"Sj\u00f6green GK, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of (177)Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07362-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07362-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07362-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:31:46Z","timestamp":1762327906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07362-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7362"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07362-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Independent Ethics Committee of Xijing Hospital (KY20232207-F-1) and registered on the Chinese Clinical Trial Registry (ChiCTR2300074096).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consents were obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors approved the publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing financial interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}